Evidence map›Paper›PMID 18623377›Full record

Trial reportCancer2008

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.

Ajay K Gopal, Tracee L Metcalfe, Ted A Gooley, John M Pagel, Stephen H Petersdorf, William I Bensinger, Leona Holmberg, David G Maloney, Oliver W Press

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma.Journal of the National Comprehensive Cancer Network : JNCCN · 2011
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ajay K GopalDepartment of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA. agopal@u.washington.edu
Tracee L Metcalfe
Ted A Gooley
John M Pagel
Stephen H Petersdorf
William I Bensinger
Leona Holmberg
David G Maloney
Oliver W Press
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · US

Funding

TREATMENT OF B-CELL LYMPHOMAP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOPAL, AJAY · 1988 to 2015
$29.3M
Radioimmunotherapy of CD20+ Lymphomas &CD45+LeukemiasK08CA095448 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PAGEL, JOHN M · 2004 to 2008
$668k
OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMAK23CA085479 · NCI · UNIVERSITY OF WASHINGTON · PI GOPAL, AJAY · 2000 to 2005
$654k
NCI NIH HHS K08 CA095448NCI NIH HHS K08CA095448NCI NIH HHS K23 CA085479NCI NIH HHS K23CA85479NCI NIH HHS P01 CA044991NCI NIH HHS P01CA44991
6 · The paper itself

Abstract

backgroundHigh-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease. We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients.

methodsSixty-four chemoresistant HL patients underwent HDT followed by ASCT at our center. Baseline characteristics included median age = 35 years (range, 14-59 years), stage III/IV = 49 (77%), nodular sclerosis histology = 51 (80%), and prior radiation = 32 (50%). Twenty-six patients (41%) received total body irradiation (TBI)-based regimens, and 38 (59%) underwent non-TBI conditioning.

resultsThe estimated 5-year overall survival (OS) and progression-free survival (PFS) were 31% and 17%, respectively (median follow-up = 4.2 years). Multivariate analysis only identified year of transplant as independently associated with improved OS (P = .008) and PFS (P = .04), with patients receiving transplants in later years having better outcome. The probabilities of 3-year PFS for patients receiving transplants during 1986 to 1989, 1990 to July 1993, August 1993 to 1999, and 2000 to 2005 were 9%, 21%, 33%, and 31%, respectively.

conclusionsThese data suggest that HDT and ASCT may result in prolonged remissions and survival for a subset of chemoresistant HL patients, with improved outcomes in patients receiving transplants more recently.

Indexed as

Drug Resistance, NeoplasmHematopoietic Stem Cell TransplantationSalvage TherapyAntineoplastic Combined Chemotherapy ProtocolsFemaleHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingSurvival RateTransplantation, AutologousTransplantation ConditioningTreatment Outcome

Identifiers

PMID18623377
PMCPMC2700660
OpenAlexW2015388914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.